Greenberg has been widely recognized for his early work creating the genetically engineered TRAMP mouse model for prostate cancer and demonstrating the oncogenic potential of mutated androgen receptors. Atreca’s proprietary Immune Repertoire Capture (IRC) technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. ![]() Greenberg was as a Full Member at the Fred Hutchinson Cancer Research Center in Seattle and Associate (Tenured) Professor at Baylor College of Medicine in Houston. Greenberg was Senior Vice President for Translational Medicine at Checkmate Pharmaceuticals supporting an innovative CpG based therapy, Vice President of Global Oncology Research at MedImmune/AstraZeneca where his group delivered therapeutics against PDL1, OX40 and other targets and Senior Director of Oncology Research at Pfizer where his group helped delivered a therapeutic targeting 41BB. During his career in Pharma and Biotech, Dr. Greenberg leads a multi-disciplinary research and development team that is delivering unique therapeutics based on anti-cancer antibodies and T cell receptors identified from the immune repertoires of elite responder patients in multiple indications.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |